David Goldblatt

List of Publications by Citations

Source: https://exaly.com/author-pdf/2763300/david-goldblatt-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

250 papers	11,596 citations	58 h-index	98 g-index
289 ext. papers	14,018 ext. citations	8.2 avg, IF	6.39 L-index

#	Paper	IF	Citations
250	Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *New England Journal of Medicine*, **2021**, 384, 2202-2211	59.2	435
249	The fundamental link between pneumococcal carriage and disease. *Expert Review of Vaccines*, **2012**, 11, 841-55	5.2	408
248	Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. *Lancet Infectious Diseases, The*, **2014**, 14, 839-46	25.5	330
247	Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. *Clinical Infectious Diseases*, **2015**, 61, 1637-44	11.6	310
246	Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. *Vaccine*, **2003**, 21, 3265-72	4.1	283
245	Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. *Infection and Immunity*, **2001**, 69, 1568-73	3.7	281
244	Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*, **2021**, 39, 4423-4428	4.1	277
243	Dense genomic sampling identifies highways of pneumococcal recombination. *Nature Genetics*, **2014**, 46, 305-309	36.3	269
242	Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. *Vaccine Journal*, **2003**, 10, 514-9		251
241	Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. *Lancet, The*, **2007**, 369, 1440-1451	49	216
240	Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. *Journal of Infectious Diseases*, **2001**, 183, 160-3	7	200
239	Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. *Journal of Infectious Diseases*, **1998**, 177, 1112-5	7	193
238	Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. *Journal of Infectious Diseases*, **2005**, 192, 387-93	7	189
237	Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. *Lancet, The*, **1999**, 354, 2063-8	40	186
236	Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. *Clinical and Experimental Immunology*, **2008**, 152, 211-8	6.2	173
235	Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. *Lancet Infectious Diseases, The*, **2007**, 7, 597-606	25.5	173
234	Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. *Vaccine Journal*, **2006**, 13, 165-9		165

233	Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. *Clinical and Experimental Immunology*, **2002**, 128, 118-23	6.2	156
232	Pneumococcal vaccination in developing countries. *Lancet, The*, **2006**, 367, 1880-2	40	142
231	Comprehensive identification of single nucleotide polymorphisms associated with beta-lactam resistance within pneumococcal mosaic genes. *PLoS Genetics*, **2014**, 10, e1004547	6	132
230	Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. *Pediatric Infectious Disease Journal*, **2006**, 25, 312-9	3.4	130
229	Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. *Journal of Infectious Diseases*, **2006**, 194, 1745-52	7	128
228	The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. *Clinical Infectious Diseases*, **2009**, 49, 1318-25	11.6	125
227	Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. *Journal of Clinical Microbiology*, **2011**, 49, 1784-9	9.7	118
226	Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). *Journal of Leukocyte Biology*, **2003**, 73, 591-9	6.5	117
225	Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 855-64	10.2	110
224	Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. *Vaccine*, **2008**, 26, 4434-45	4.1	107
223	Colitis in chronic granulomatous disease. *Archives of Disease in Childhood*, **2001**, 84, 147-51	2.2	106
222	Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. *Clinical and Experimental Immunology*, **2007**, 148, 79-84	6.2	105
221	Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. *Vaccine Journal*, **2006**, 13, 356-60		105
220	Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. *Journal of Immunology*, **2009**, 183, 5622-9	5.3	102
219	Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. *Journal of Infectious Diseases*, **2002**, 186, 1353-7	7	99
218	A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. *PLoS ONE*, **2012**, 7, e38271	3.7	89
217	Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. *Infection and Immunity*, **2003**, 71, 5549-55	3.7	84
216	Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1150-5	11.5	81

215	Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. *Infection and Immunity*, **2002**, 70, 4946-54	3.7	80
214	The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. *Journal of Infectious Diseases*, **1999**, 180, 538-41	7	78
213	Establishment of a new human pneumococcal standard reference serum, 007sp. *Vaccine Journal*, **2011**, 18, 1728-36		77
212	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S109-18	3.4	76
211	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S140-51	3.4	75
210	Chorioretinal lesions in patients and carriers of chronic granulomatous disease. *Journal of Pediatrics* , **1999**, 134, 780-3	3.6	75
209	Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. *Infection and Immunity*, **2004**, 72, 5383-91	3.7	74
208	Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. *Journal of Infectious Diseases*, **2001**, 184, 1617-20	7	74
207	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S152-60	3.4	72
206	Follow up of patients with chronic granulomatous disease diagnosed since 1990. *Clinical and Experimental Immunology*, **2000**, 120, 351-5	6.2	72
205	Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S161-71	3.4	71
204	Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial. *Lancet Infectious Diseases, The*, **2018**, 18, 171-179	25.5	70
203	Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. *Vaccine*, **1999**, 18, 641-6	4.1	69
202	Immunogenetic analysis of the immune response to pneumococcal polysaccharide. *European Journal of Immunology*, **2000**, 30, 1214-23	6.1	68
201	Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. *Journal of Infectious Diseases*, **2006**, 194, 385-90	7	66
200	Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. *Journal of Infectious Diseases*, **2001**, 184, 377-80	7	65
199	An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. *Journal of Clinical Microbiology*, **2000**, 38, 2043-50	9.7	65
198	Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression. *European Journal of Immunology*, **2000**, 30, 1691-7	6.1	62

197	The nature of colitis in chronic granulomatous disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2003**, 36, 623-31	2.8	60
196	Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood. *Journal of Infectious Diseases*, **1990**, 162, 1128-35	7	59
195	A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. *Vaccine Journal*, **1999**, 6, 581-6		59
194	Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S172-81	3.4	58
193	Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. *Pediatric Infectious Disease Journal*, **2010**, 29, 401-5	3.4	57
192	Naturally Acquired Human Immunity to Pneumococcus Is Dependent on Antibody to Protein Antigens. *PLoS Pathogens*, **2017**, 13, e1006137	7.6	57
191	Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. *Journal of Clinical Immunology*, **2013**, 33, 8-13	5.7	56
190	Clinical manifestations of disease in X-linked carriers of chronic granulomatous disease. *Journal of Clinical Immunology*, **2013**, 33, 1276-84	5.7	55
189	Dendritic cell anergy results from endotoxemia in severe malnutrition. *Journal of Immunology*, **2009** , 183, 2818-26	5.3	55
188	Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. *Clinical and Experimental Immunology*, **2008**, 151, 51-60	6.2	55
187	Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. *Journal of Infectious Diseases*, **2002**, 185, 397-400	7	54
186	Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. *Vaccine Journal*, **2011**, 18, 135-42		53
185	Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. *Vaccine Journal*, **2003**, 10, 1019-24		52
184	A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. *Journal of Rheumatology*, **2018**, 45, 733-744	4.1	50
183	Genome-wide identification of lineage and locus specific variation associated with pneumococcal carriage duration. *ELife*, **2017**, 6,	8.9	50
182	Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. *PLoS ONE*, **2013**, 8, e74906	3.7	49
181	Clinical relevance of lower Hib response in DTPa-based combination vaccines. *Vaccine*, **2001**, 19, 2280-5	4.1	49
180	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature*, **2021**,	50.4	49

179	Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. *Journal of Clinical Virology*, **2020**, 130, 104572	14.5	49
178	Recent developments in bacterial conjugate vaccines. *Journal of Medical Microbiology*, **1998**, 47, 563-7	3.2	48
177	X-linked lymphoproliferative disease: three atypical cases. *Clinical and Experimental Immunology*, **2001**, 126, 126-30	6.2	45
176	Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. *Clinical Infectious Diseases*, **2011**, 53, 663-70	11.6	44
175	Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. *Vaccine Journal*, **2004**, 11, 1100-4		44
174	Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. *Lancet, The*, **2003**, 362, 449-50	40	44
173	The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. *PLoS Medicine*, **2015**, 12, e1001839	11.6	42
172	Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. *Clinical Microbiology and Infection*, **2013**, 19, E551-8	9.5	42
171	Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S119-29	3.4	41
170	Colonisation endpoints in Streptococcus pneumoniae vaccine trials. *Vaccine*, **2013**, 32, 153-8	4.1	39
169	Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. *Vaccine*, **2008**, 26, 3719-26	4.1	38
168	Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. *Vaccine Journal*, **2007**, 14, 1362-9		38
167	Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. *Tropical Medicine and International Health*, **2006**, 11, 1529-41	2.3	38
166	Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. *Vaccine*, **2002**, 20, 2592-6	4.1	37
165	Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. *Lancet Haematology,the*, **2021**, 8, e542-e544	14.6	37
164	Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 628-630.e6	11.5	36
163	RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. *Infection and Immunity*, **2012**, 80, 451-60	3.7	36
162	Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). *Journal of Immunological Methods*, **1997**, 205, 67-72	2.5	35

161	Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. *Pediatric Infectious Disease Journal*, **1995**, 14, 129-35	3.4	35
160	Hospital admissions in children due to pneumococcal pneumonia in England. *Journal of Infection*, **1998**, 37, 54-8	18.9	34
159	Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study. *The Lancet Global Health*, **2016**, 4, e185-94	13.6	34
158	The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. *Vaccine*, **2010**, 28, 4763-70	4.1	33
157	Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. *Immunology*, **1996**, 88, 169-73	7.8	33
156	Role of cell wall polysaccharide in the assessment of IgG antibodies to the capsular polysaccharides of Streptococcus pneumoniae in childhood. *Journal of Infectious Diseases*, **1992**, 166, 632-4	7	33
155	Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. *Pediatric Infectious Disease Journal*, **1996**, 15, 1097-101	3.4	33
154	The Efficacy and Duration of Protection of Pneumococcal Conjugate Vaccines Against Nasopharyngeal Carriage: A Meta-regression Model. *Pediatric Infectious Disease Journal*, **2015**, 34, 858-64	3.4	32
153	The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity. *Journal of Immunological Methods*, **1993**, 166, 281-5	2.5	32
152	Climate induces seasonality in pneumococcal transmission. *Scientific Reports*, **2015**, 5, 11344	4.9	31
151	A longitudinal study of the infant nasopharyngeal microbiota: The effects of age, illness and antibiotic use in a cohort of South East Asian children. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005975	4.8	31
150	Conjugate Hib vaccines. *Lancet, The*, **2003**, 361, 360-1	40	31
149	Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. *PLoS ONE*, **2014**, 9, e85459	3.7	31
148	Serocorrelates of protection against infant group B streptococcus disease. *Lancet Infectious Diseases, The*, **2019**, 19, e162-e171	25.5	30
147	Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. *Vaccine*, **2013**, 31, 1453-7	4.1	30
146	The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. *Vaccine*, **2011**, 29, 2999-3007	4.1	30
145	Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. *Pediatric Infectious Disease Journal*, **2012**, 31, 616-22	3.4	30
144	Pneumococcal polysaccharides interact with human dendritic cells. *Infection and Immunity*, **2006**, 74, 1890-5	3.7	30

143	An Experimental Group A Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model. *MBio*, **2019**, 10,	7.8	29
142	Neonatal Immunization: Rationale, Current State, and Future Prospects. *Frontiers in Immunology*, **2018**, 9, 532	8.4	29
141	Recent advances in chronic granulomatous disease. *Journal of Infection*, **2014**, 69 Suppl 1, S32-5	18.9	29
140	Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. *MAbs*, **2017**, 9, 1282-1296	6.6	29
139	Chronic granulomatous disease: from genetic defect to clinical presentation. *Advances in Experimental Medicine and Biology*, **2005**, 568, 67-87	3.6	28
138	Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. *Pediatric Infectious Disease Journal*, **2002**, 21, 940-7	3.4	28
137	Antibody response to outer membrane proteins of Moraxella catarrhalis in children with otitis media. *Pediatric Infectious Disease Journal*, **1999**, 18, 982-8	3.4	28
136	Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants. *PLoS ONE*, **2015**, 10, e0144739	3.7	27
135	CD4 counts decline despite nutritional recovery in HIV-infected Zambian children with severe malnutrition. *Pediatrics*, **2009**, 123, e347-51	7.4	26
134	Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgG. *Vaccine Journal*, **2011**, 18, 1744-51		26
133	Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. *Vaccine Journal*, **2007**, 14, 1328-33		26
132	High rates of pneumonia in children under two years of age in a South East Asian refugee population. *PLoS ONE*, **2013**, 8, e54026	3.7	25
131	Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. *PLoS ONE*, **2013**, 8, e51460	3.7	25
130	Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy. *Pediatric Infectious Disease Journal*, **2017**, 36, 1186-1192	3.4	24
129	The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination. *Proceedings of the Royal Society B: Biological Sciences*, **2013**, 280, 20131939	4.4	24
128	Current treatment options for chronic granulomatous disease. *Expert Opinion on Pharmacotherapy*, **2002**, 3, 857-63	4	24
127	The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S130-9	3.4	23
126	Probable mother to infant transmission of Pneumocystis jiroveci from an HIV-infected woman to her HIV-uninfected infant. *Aids*, **2005**, 19, 1548-9	3.5	23

125	Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. *Archives of Disease in Childhood: Fetal and Neonatal Edition*, **2004**, 89, F269-71	4.7	22
124	Genomics Reveals the Worldwide Distribution of Multidrug-Resistant Serotype 6E Pneumococci. *Journal of Clinical Microbiology*, **2015**, 53, 2271-85	9.7	21
123	Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. *Aids*, **2014**, 28, 2033-43	3.5	21
122	Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. *Archives of Disease in Childhood*, **1996**, 75, 159-61	2.2	21
121	Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial. *Vaccine*, **2017**, 35, 7181-7186	4.1	20
120	Assignment of Opsonic Values to Pneumococcal Reference Serum 007sp for Use in Opsonophagocytic Assays for 13 Serotypes. *Vaccine Journal*, **2017**, 24,		19
119	Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. *Vaccine Journal*, **2011**, 18, 367-72		19
118	An enzyme-linked immunosorbent assay for the determination of human IgG subclass antibodies directed against Branhamella catarrhalis. *Journal of Immunological Methods*, **1990**, 128, 219-25	2.5	19
117	Increased expression of interleukin-13 but not interleukin-4 in CD4+ cells from patients with the hyper-IgE syndrome. *Clinical and Experimental Immunology*, **2002**, 128, 532-7	6.2	18
116	Prenatal diagnosis in two families with autosomal, p47(phox)-deficient chronic granulomatous disease due to a novel point mutation in NCF1. *Prenatal Diagnosis*, **2002**, 22, 235-40	3.2	18
115	Preparation of human-mouse heterohybridomas against an immunising antigen. *Journal of Immunological Methods*, **2000**, 246, 187-202	2.5	18
114	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. *Pediatrics*, **2016**, 138,	7.4	18
113	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. *Vaccine*, **2019**, 37, 3190-3198	4.1	17
112	Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: a randomized phase I clinical trial. *Vaccine*, **2014**, 32, 5266-70	4.1	17
111	Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands. *Frontiers in Pharmacology*, **2014**, 5, 8	5.6	17
110	Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage. *Vaccine*, **2017**, 35, 4652-4657	4.1	17
109	The influence of paediatric HIV infection on circulating B cell subsets and CXCR5(+) T helper cells. *Clinical and Experimental Immunology*, **2015**, 181, 110-7	6.2	17
108	A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma. *Vox Sanguinis*, **2002**, 83, 17-22	3.1	17

107	Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing Isolates. *Journal of Infectious Diseases*, **2017**, 215, 713-722	7	17
106	Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia. *Vaccine Journal*, **2016**, 23, 379-85		16
105	Development of an opsonophagocytic killing assay for group a streptococcus. *Vaccine*, **2018**, 36, 3756-3763	4.1	15
104	Assessment of Streptococcus pneumoniae pilus islet-1 prevalence in carried and transmitted isolates from mother-infant pairs on the Thailand-Burma border. *Clinical Microbiology and Infection*, **2012**, 18, 970-5	9.5	15
103	Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. *Vaccine*, **2010**, 28, 6915-22	4.1	15
102	Characterisation of an outer membrane protein of Moraxella catarrhalis. *FEMS Immunology and Medical Microbiology*, **1997**, 19, 231-6		15
101	Cross-sectional prevalence of SARS-CoV-2 antibodies in healthcare workers in paediatric facilities in eight countries. *Journal of Hospital Infection*, **2021**, 110, 60-66	6.9	15
100	Design questions for Streptococcus pneumoniae vaccine trials with a colonisation endpoint. *Vaccine*, **2013**, 32, 159-64	4.1	14
99	Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. *Vaccine*, **2015**, 33, 6675-83	4.1	14
98	Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. *Vaccine Journal*, **2007**, 14, 397-403		14
97	Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. *Vaccine*, **2020**, 38, 399-410	4.1	14
96	Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population. *Arthritis Care and Research*, **2016**, 68, 853-60	4.7	13
95	Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia. *Emerging Infectious Diseases*, **2015**, 21, 2080-3	10.2	13
94	Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule. *Vaccine*, **2015**, 33, 648-55	4.1	13
93	Field evaluation of culture plus latex sweep serotyping for detection of multiple pneumococcal serotype colonisation in infants and young children. *PLoS ONE*, **2013**, 8, e67933	3.7	13
92	Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies. *Infection and Immunity*, **2006**, 74, 1025-31	3.7	13
91	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. *Pediatric Infectious Disease Journal*, **2016**, 35, 787-93	3.4	13
90	A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Challenge. *Infection and Immunity*, **2019**, 87,	3.7	13

89	Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. *Biologicals*, **2018**, 56, 29-38	1.8	13
88	Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. *Vaccine*, **2020**, 38, 3339-3350	4.1	12
87	Maternal and neonatal pneumococcal vaccination - where are we now?. *Expert Review of Vaccines*, **2016**, 15, 1305-17	5.2	12
86	Interchangeability of conjugated Haemophilus influenzae type b vaccines during primary immunisation of infants. *BMJ: British Medical Journal*, **1996**, 312, 817-8		12
85	Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam. *Human Vaccines and Immunotherapeutics*, **2018**, 14, 1939-1947	4.4	12
84	Detection of respiratory viruses by PCR assay of nasopharyngeal swabs stored in skim milk-tryptone-glucose-glycerol transport medium. *Journal of Clinical Microbiology*, **2011**, 49, 2311-3	9.7	11
83	Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. *Lancet Infectious Diseases, The*, **2021**, 21, 834-846	25.5	11
82	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. *Clinical Infectious Diseases*, **2021**,	11.6	11
81	Vaccine-Induced Th1-Type Response Protects against Invasive Group A Infection in the Absence of Opsonizing Antibodies. *MBio*, **2020**, 11,	7.8	10
80	Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. *Vaccine*, **2017**, 35, 5186-5193	4.1	10
79	Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S182-7	3.4	10
78	Towards a population-based threshold of protection for COVID-19 vaccines.. *Vaccine*, **2021**, 40, 306-306	4.1	10
77	Early-life and contemporaneous nutritional and environmental predictors of antibody response to vaccination in young Gambian adults. *Vaccine*, **2012**, 30, 4842-8	4.1	9
76	A high burden of respiratory syncytial virus associated pneumonia in children less than two years of age in a South East Asian refugee population. *PLoS ONE*, **2012**, 7, e50100	3.7	9
75	Cognitive ability in children with chronic granulomatous disease: a comparison of those managed conservatively with those who have undergone hematopoietic stem cell transplant. *Neuropediatrics* , **2013**, 44, 230-2	1.6	9
74	Measles vaccination and inflammatory bowel disease. *Lancet, The*, **1998**, 351, 755-6	40	9
73	Humoral immunity in children with biliary atresia splenic malformation syndrome. *European Journal of Pediatrics*, **2003**, 162, 539-540	4.1	9
72	Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 604-613	10.2	9

71	Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp. *Vaccine Journal*, **2015**, 22, 1154-9		8
70	Bacteria, polysaccharides, vaccines and boosting: measuring and maintaining population immunity. *Archives of Disease in Childhood*, **2008**, 93, 646-7	2.2	8
69	Transfusion associated graft-versus-host disease in DiGeorge syndrome: Index case report with survey of screening procedures and use of irradiated blood components. *Cardiology in the Young*, **1996**, 6, 222-227	1	8
68	A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults. *Pediatric Infectious Disease Journal*, **2020**, 39, 345-351	3.4	8
67	Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. *Lancet Infectious Diseases, The*, **2019**, 19, 156-164	25.5	8
66	SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK: A retrospective cohort study. *Lancet Regional Health - Europe, The*, **2021**, 6, 100127		8
65	Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. *Bioanalysis*, **2020**, 12, 1363-1375	2.1	7
64	Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies. *Vaccine Journal*, **2015**, 22, 404-12		7
63	Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae. *European Journal of Immunology*, **2009**, 39, 1527-35	6.1	7
62	Pericardial effusions in two boys with chronic granulomatous disease. *Pediatric Radiology*, **1999**, 29, 820-2	2.8	7
61	An Analytical Model Applied to a Multicenter Pneumococcal Enzyme-Linked Immunosorbent Assay Study. *Journal of Clinical Microbiology*, **2000**, 38, 2043-2050	9.7	7
60	Effect of Maternally Derived Anti-protein and Anticapsular IgG Antibodies on the Rate of Acquisition of Nasopharyngeal Carriage of Pneumococcus in Newborns. *Clinical Infectious Diseases*, **2018**, 66, 121-130	11.6	6
59	Emotional and behavioural difficulties in chronic granulomatous disease. *Archives of Disease in Childhood*, **2012**, 97, 87	2.2	6
58	Extremely high SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK		6
57	Correlates of protection against SARS - CoV -2 infection and COVID-19 disease. *Immunological Reviews*,	11.3	6
56	Raised Serum IL-8 Levels Are Associated with Excessive Fatigue in Female Carriers of X-Linked Chronic Granulomatous Disease in the UK. *Journal of Clinical Immunology*, **2017**, 37, 279-281	5.7	5
55	Health-Related Quality of Life and Emotional Health in X-Linked Carriers of Chronic Granulomatous Disease in the United Kingdom. *Journal of Clinical Immunology*, **2019**, 39, 195-199	5.7	5
54	Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets. *Infection and Immunity*, **2015**, 83, 2889-96	3.7	5

53	Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells. *Immunology*, **2008**, 125, 469-79	7.8	5
52	The Immunobiology of Polysaccharide and Conjugate Vaccines67-82		5
51	Preclinical Development of Virulence-attenuated Strains Able to Enhance Protective Immunity against Pneumococcal Infection. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1037-1041	10.2	5
50	Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae. *Vaccine*, **2018**, 36, 4255-4264	4.1	5
49	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.. *Nature Cancer*, **2022**,	15.4	5
48	SARS-CoV-2: from herd immunity to hybrid immunity.. *Nature Reviews Immunology*, **2022**,	36.5	5
47	An Uncommon Site of Colonization Leading to Recurrent Pneumococcal Disease. *Open Forum Infectious Diseases*, **2017**, 4, ofw257	1	4
46	Comparison between a new multiplex electrochemiluminescence assay and the WHO reference enzyme-linked immunosorbent assay to measure serum antibodies against pneumococcal serotype-specific polysaccharides. *Vaccine*, **2019**, 37, 2208-2215	4.1	4
45	Antibody Response is More Likely to Pneumococcal Proteins Than to Polysaccharide After HIV-associated Invasive Pneumococcal Disease. *Journal of Infectious Diseases*, **2015**, 212, 1093-9	7	4
44	Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I. *Vaccine*, **2018**, 36, 4944-4951	4.1	4
43	Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose. *Vaccine*, **2013**, 31, 5834-42	4.1	4
42	Natural IgM antibodies in the immune defence against neoehrlichiosis. *Infectious Diseases*, **2017**, 49, 809-816	3.1	4
41	Why do we need a systematic review of pneumococcal conjugate vaccine dosing schedules?. *Pediatric Infectious Disease Journal*, **2014**, 33 Suppl 2, S107-8	3.4	4
40	Reply to Bogaert et al.. *Journal of Infectious Diseases*, **2006**, 194, 1618-1619	7	4
39	Hematopoietic-cell transplantation for chronic granulomatous disease. *New England Journal of Medicine*, **2001**, 345, 377-8	59.2	4
38	Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1104-1107	11.5	4
37	A Population-Based Threshold of Protection for COVID-19 Vaccines		4
36	The duopoly of ten-valent and 13-valent pneumococcal conjugate vaccines: do they differ?. *Lancet Infectious Diseases, The*, **2019**, 19, 453-454	25.5	3

35	Assignment of Weight-Based Antibody Units for Four Additional Serotypes to a Human Antipneumococcal Standard Reference Serum, 007sp. *Vaccine Journal*, **2017**, 24,		3
34	Persistence of IgG antibody following routine infant immunization with the 7-valent pneumococcal conjugate vaccine. *Pediatric Infectious Disease Journal*, **2015**, 34, e138-42	3.4	3
33	Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. *Journal of Infectious Diseases*, **2021**,	7	3
32	Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. *Lancet Infectious Diseases, The*, **2020**, 20, 1426-1436	25.5	3
31	Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial. *Lancet Infectious Diseases, The*, **2021**, 21, 688-696	25.5	3
30	An Opsonophagocytic Killing Assay for the Evaluation of Group A Streptococcus Vaccine Antisera. *Methods in Molecular Biology*, **2020**, 2136, 323-335	1.4	3
29	The indirect effect of pneumococcal conjugate vaccine. *The Lancet Global Health*, **2017**, 5, e6-e7	13.6	2
28	Autism, inflammatory bowel disease, and MMR vaccine. *Lancet, The*, **1998**, 351, 1355-6; author reply 1356	40	2
27	Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2		2
26	Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs		2
25	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2		2
24	Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment. *Clinical Infectious Diseases*, **2020**, 71, 1271-1280	11.6	2
23	Generation of recombinant hyperimmune globulins from diverse B-cell repertoires. *Nature Biotechnology*, **2021**, 39, 989-999	44.5	2
22	B-cell development and pneumococcal immunity in vertically acquired HIV infection. *Aids*, **2016**, 30, 1867-76	3.5	2
21	Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation. *Scientific Reports*, **2018**, 8, 15376	4.9	2
20	Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial. *Lancet HIV,the*, **2021**, 8, e408-e419	7.8	2
19	The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity to. *Frontiers in Immunology*, **2020**, 11, 611661	8.4	2
18	Immune response and host-pathogen interactions. *Methods in Molecular Medicine*, **2001**, 66, 23-39		1

17	Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam: a dynamic transmission model		1
16	Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule - AuthorsPreply. *Lancet Infectious Diseases, The*, **2018**, 18, 382-383	25.5	1
15	Antibodies to Seasonal Coronaviruses Rarely Cross-React With SARS-CoV-2: Findings From an African Birth Cohort. *Pediatric Infectious Disease Journal*, **2021**, 40, e516-e519	3.4	1
14	Immunogenetic analysis of the immune response to pneumococcal polysaccharide **2000**, 30, 1214		1
13	Maintained partial protection against despite B-cell depletion in mice vaccinated with a pneumococcal glycoconjugate vaccine.. *Clinical and Translational Immunology*, **2022**, 11, e1366	6.8	1
12	WHO guidelines for treatment of severe pneumonia AuthorsPreply. *Lancet, The*, **2007**, 370, 385-386	40	0
11	Corrected and Republished from: "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Challenge".. *Infection and Immunity*, **2022**, 90, e0084618a	3.7	0
10	Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. *Vaccines*, **2022**, 10, 850	5.3	0
9	Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines - AuthorsPreply. *Lancet Infectious Diseases, The*, **2019**, 19, 693-694	25.5	
8	Nonsense in Public Places: Songs of Black Vocal Rhythm and Blues or Doo-Wop. *Journal of Aesthetics and Art Criticism*, **2013**, 71, 101-110	0.3	
7	Umhlaba 1913–2013. *Social Dynamics*, **2013**, 39, 327-352	0.2	
6	Infection risk in ANCA-associated vasculitis. *Presse Medicale*, **2013**, 42, 665-666	2.2	
5	Hib IgG persistence following early booster dose. *Archives of Disease in Childhood*, **2005**, 90, 329	2.2	
4	Opsonophagocytic Killing Assay to Measure Anti-Group A Streptococcus Antibody Functionality in Human Serum. *Methods in Molecular Biology*, **2022**, 2414, 373-386	1.4	
3	Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing. *Vaccine*, **2020**, 38, 7834-7841	4.1	
2	Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers. *Pediatric Infectious Disease Journal*, **2021**, 40, 937-943	3.4	
1	Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients. *Vaccines*, **2022**, 10, 725	5.3	